Physician profile
Edward Yavitz
NPI 1902878358
$4,736.66
in general payments reported to CMS, 2019-2025
26 companies · $1,753 in 2025
The $1,753 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $255 · 2021: $163 · 2022: $371 · 2023: $594 · 2024: $1,126 · 2025: $1,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,472.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $612.56 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $576.08 | 2019-2025 | Cequa, Xelpros |
| Amgen INC. | $518.66 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $445.42 | 2019-2025 | Hydrus Microstent, Rocklatan, Tryptyr |
| Abbvie INC. | $289.15 | 2022-2025 | Durysta |
| Tarsus Pharmaceuticals, INC. | $261.06 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $259.64 | 2023 | Tepezza |
| Harrow Eye, LLC | $244.74 | 2024-2025 | Vevye, Iheezo |
| Oyster Point Pharma, INC. | $212.42 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $167.44 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $136.52 | 2019-2021 | |
| Biotissue Holdings INC. | $136.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $134.74 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $115.46 | 2025 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $112.26 | 2025 | Syfovre |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $105.57 | 2025 | |
| Shire North American Group INC | $64.59 | 2019 | |
| Thea Pharma INC. | $59.32 | 2022-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $58.43 | 2019 | |
| Ani Pharmaceuticals, INC. | $53.37 | 2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $45.09 | 2025 | Izervay |
| Sight Sciences, INC. | $34.67 | 2019-2021 | |
| Ivantis, INC | $29.85 | 2020 | |
| Dompe US, INC. | $28.62 | 2024 | Oxervate |
| Genentech USA, INC. | $20.29 | 2025 | Vabysmo |
| Kala Pharmaceuticals, INC. | $14.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Yavitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.